CU-CPT-9a - Toll-like Receptor (TLR) Antagonist - 生命科學(xué)試劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemECU-CPT-9aCat. No.: HY-112667CAS No.: 2165340-32-7分式: CHNO分量: 265.31作靶點(diǎn): Toll-like Receptor (TLR)作通路: Immunology/Inflammation儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 150 mg/mL (565.38

2、 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 3.7692 mL 18.8459 mL 37.6918 mL5 mM 0.7538 mL 3.7692 mL 7.5384 mL10 mM 0.3769 mL 1.8846 mL 3.7692 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn) 請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?，配制前?qǐng)先配制澄清的儲(chǔ)備液，再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性，體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清的

3、儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (9.42 mM); Clear solution2. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (9.42 mM); Clear solution3. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL

4、(9.42 mM); Clear solution1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEBIOLOGICAL ACTIVITY物活性 CU-CPT-9a是TLR8 的特異性拮抗劑，其 IC50 值為 0.5 nM。IC50 & Target TLR80.5 nM (IC50)體外研究 CU-CPT-9a is a specific TLR8 antagonist, with an IC50 of 0.50.1 nM. The elevation of the downstreamprotein levels induced by R8

5、48 can be reversed by CU-CPT-9a in a dose-dependent manner. By contrast,the expression of TRIF and IRF3 (cytoplasmic and nuclear) are only responsive to TLR4 and TLR3,independent of TLR837. The expression levels of TRIF and IRF3 do not show significant change in THP-1cells upon treatment of R848, no

6、r do they change with the treatment of CU-CPT-9a. CU-CPT8m and CU-CPT-9a both significantly suppress the TNF- level in a dose-dependent manner, which is in agreement withprevious reports of TLR8 involvement in these autoimmune diseases 1.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Eur J Pharmacol. 2019 Mar 5;846:12-22.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Zhang S, et al. Small-molecule inhibition of TLR8 through stabilization of its resting state. Nat Chem Biol. 2018 Jan;14(1):58-64.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use on